
<table style="border-collapse:collapse;" class=table-fill border=1>
<thead>
<tr>
  <th id="tableHTML_header_1">Group</th>
  <th id="tableHTML_header_2">Interventions</th>
  <th id="tableHTML_header_3">Descriptions/mechanisms of action</th>
  <th id="tableHTML_header_4">text</th>
  <th id="tableHTML_header_5">More information</th>
</tr>
</thead>
<tbody>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">acetyl-L-carnitine</td>
  <td id="tableHTML_column_3">acetyl-L-carnitine is a acetylated form of the amino acid derivative L-carnitine, which aids mitochondrial fatty acid metabolism.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about acetyl-L-carnitine</div><div class='header_tab'>Type of intervention.</div>acetyl-L-carnitine is a <u>Nutraceutical</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>acetyl-L-carnitine acetyl-L-carnitine is a acetylated form of the amino acid derivative L-carnitine, which aids mitochondrial fatty acid metabolism.. <div class='header_tab'>Indication for this intervention.</div>The use of acetyl-L-carnitine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">alpha-lipoic acid</td>
  <td id="tableHTML_column_3">alpha-lipoic acid is a antioxidant with insulin-mimetic and anti-inflammatory activity</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about alpha-lipoic acid</div><div class='header_tab'>Type of intervention.</div>alpha-lipoic acid is a <u>Nutraceutical</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>alpha-lipoic acid alpha-lipoic acid is a antioxidant with insulin-mimetic and anti-inflammatory activity. <div class='header_tab'>Indication for this intervention.</div>The use of alpha-lipoic acid in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">acetylsalicylic acid</td>
  <td id="tableHTML_column_3">acetylsalicylic acid is a anti-inflammatory, platelet aggregation inhibitor</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about acetylsalicylic acid</div><div class='header_tab'>Type of intervention.</div>acetylsalicylic acid is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is acetylsalicylic acid is a anti-inflammatory, platelet aggregation inhibitor. <div class='header_tab'>Indication for this intervention.</div>The use of acetylsalicylic acid in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">agomelatin</td>
  <td id="tableHTML_column_3">agomelatin is a melatonin, serotonin receptor agonist (Mel1,Mel2), receptor antagonist (5-HT2B, 5-HT2C)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about agomelatin</div><div class='header_tab'>Type of intervention.</div>agomelatin is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is agomelatin is a melatonin, serotonin receptor agonist (Mel1,Mel2), receptor antagonist (5-HT2B, 5-HT2C). <div class='header_tab'>Indication for this intervention.</div>The use of agomelatin in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">allopurinol</td>
  <td id="tableHTML_column_3">allopurinol is a xanthine oxidase inhibitor</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about allopurinol</div><div class='header_tab'>Type of intervention.</div>allopurinol is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is allopurinol is a xanthine oxidase inhibitor. <div class='header_tab'>Indication for this intervention.</div>The use of allopurinol in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">amitriptyline</td>
  <td id="tableHTML_column_3">amitriptyline is a norepinephrine, serotonin reuptake inhibitor, receptor antagonist (5-HT2)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about amitriptyline</div><div class='header_tab'>Type of intervention.</div>amitriptyline is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is amitriptyline is a norepinephrine, serotonin reuptake inhibitor, receptor antagonist (5-HT2). <div class='header_tab'>Indication for this intervention.</div>The use of amitriptyline in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">aripiprazole</td>
  <td id="tableHTML_column_3">aripiprazole is a dopamine, serotonin receptor partial agonist (D2, 5-HT1A) receptor antagonist (5-HT2A)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about aripiprazole</div><div class='header_tab'>Type of intervention.</div>aripiprazole is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is aripiprazole is a dopamine, serotonin receptor partial agonist (D2, 5-HT1A) receptor antagonist (5-HT2A). <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> Bipolar disorder type I -Acute treatment of manic and mixed episodes with a recommeded dose of 15 mg/day with a recommeded dose of 15 mg/day up to a maximum dose of 30 mg/day up to a maximum dose of 30 mg/day </li><li> Agitation associated with bipolar mania up to a maximum dose of 30 mg/day injected IM up to a maximum dose of 30 mg/day injected IM </li><li> Bipolar I disorder  - acute  treatment of manic and mixed  episodes) - pediatric patients (age  10-17) with a recommeded dose of 10 mg/day with a recommeded dose of 10 mg/day up to a maximum dose of 30 mg/day up to a maximum dose of 30 mg/day </li><li> Maintenance treatment of bipolar I disorder, both as monotherapy and as an adjunct to lithium or valproate with a recommeded dose of The recommended dose for maintenance treatment is the same dose needed to stabilize patients during acute treatment, both for adult and pediatric patient. with a recommeded dose of The recommended dose for maintenance treatment is the same dose needed to stabilize patients during acute treatment, both for adult and pediatric patient.</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">armodafinil</td>
  <td id="tableHTML_column_3">armodafinil is a dopamine reuptake inhibitor (DAT)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about armodafinil</div><div class='header_tab'>Type of intervention.</div>armodafinil is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is armodafinil is a dopamine reuptake inhibitor (DAT). <div class='header_tab'>Indication for this intervention.</div>The use of armodafinil in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">asenapine</td>
  <td id="tableHTML_column_3">asenapine is a dopamine, serotonin, norepinephrine receptor antagonist (5-HT2, D2, NE alpha-2)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about asenapine</div><div class='header_tab'>Type of intervention.</div>asenapine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is asenapine is a dopamine, serotonin, norepinephrine receptor antagonist (5-HT2, D2, NE alpha-2). <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> Bipolar mania-adults: acute and maintenance monotherapy with a recommeded dose of 5-10 mg sublingually twice daily with a recommeded dose of 5-10 mg sublingually twice daily up to a maximum dose of 10 mg sublingually twice daily up to a maximum dose of 10 mg sublingually twice daily </li><li> Bipolar mania � pediatric patients (10 to 17 years): monotherapy with a recommeded dose of 2.5-10 mg sublingually twice daily with a recommeded dose of 2.5-10 mg sublingually twice daily up to a maximum dose of 10 mg sublingually twice daily up to a maximum dose of 10 mg sublingually twice daily </li><li> Bipolar mania � adults: as an adjunct to lithium or valproate with a recommeded dose of 5-10 mg sublingually twice daily with a recommeded dose of 5-10 mg sublingually twice daily up to a maximum dose of 10 mg sublingually twice daily up to a maximum dose of 10 mg sublingually twice daily</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">brexpiprazole</td>
  <td id="tableHTML_column_3">brexpiprazole is a dopamine, serotonin receptor partial agonist (D2, 5-HT1A) receptor antagonist (5-HT2A)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about brexpiprazole</div><div class='header_tab'>Type of intervention.</div>brexpiprazole is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is brexpiprazole is a dopamine, serotonin receptor partial agonist (D2, 5-HT1A) receptor antagonist (5-HT2A). <div class='header_tab'>Indication for this intervention.</div>The use of brexpiprazole in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Biological non-pharmacological</td>
  <td id="tableHTML_column_2">bright light therapy</td>
  <td id="tableHTML_column_3">bright light therapy is a also known as phototherapy, was originally used to treat patients with seasonal affective disorder and refers to the use of glare therapy to treat mood symptoms. The International Society of Bipolar Disorders (ISBD) Task Force on Chronobiology and Chronotherapy recommended BLT as the strongest evidence among current chronotherapeutic options in the acute treatment of bipolar depression.



Takeshima M, Utsumi T, Aoki Y, Wang Z, Suzuki M, Okajima I, Watanabe N, Watanabe K, Takaesu Y. Efficacy and safety of bright light therapy for manic and depressive symptoms in patients with bipolar disorder: A systematic review and meta-analysis. Psychiatry Clin Neurosci. 2020; 74(4):247-256. doi: 10.1111/pcn.12976.



Wang S, Zhang Z, Yao L, Ding N, Jiang L, Wu Y. Bright light therapy in the treatment of patients with bipolar disorder: A systematic review and meta-analysis. PLoS One. 2020; 15(5):e0232798. doi: 10.1371/journal.pone.0232798.



Gottlieb JF, Benedetti F, Geoffroy PA, Henriksen TEG, Lam RW, Murray G, Phelps J, Sit D, Swartz HA, Crowe M, Etain B, Frank E, Goel N, Haarman BCM, Inder M, Kallestad H, Jae Kim S, Martiny K, Meesters Y, Porter R, Riemersma-van der Lek RF, Ritter PS, Schulte PFJ, Scott J, Wu JC, Yu X, Chen S. The chronotherapeutic treatment of bipolar disorders: A systematic review and practice recommendations from the ISBD task force on chronotherapy and chronobiology. Bipolar Disord. 2019; 21(8):741-773. doi: 10.1111/bdi.12847.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about bright light therapy</div><div class='header_tab'>Type of intervention.</div>bright light therapy is a <u>Biological non-pharmacological</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>bright light therapy bright light therapy is a also known as phototherapy, was originally used to treat patients with seasonal affective disorder and refers to the use of glare therapy to treat mood symptoms. The International Society of Bipolar Disorders (ISBD) Task Force on Chronobiology and Chronotherapy recommended BLT as the strongest evidence among current chronotherapeutic options in the acute treatment of bipolar depression.



Takeshima M, Utsumi T, Aoki Y, Wang Z, Suzuki M, Okajima I, Watanabe N, Watanabe K, Takaesu Y. Efficacy and safety of bright light therapy for manic and depressive symptoms in patients with bipolar disorder: A systematic review and meta-analysis. Psychiatry Clin Neurosci. 2020; 74(4):247-256. doi: 10.1111/pcn.12976.



Wang S, Zhang Z, Yao L, Ding N, Jiang L, Wu Y. Bright light therapy in the treatment of patients with bipolar disorder: A systematic review and meta-analysis. PLoS One. 2020; 15(5):e0232798. doi: 10.1371/journal.pone.0232798.



Gottlieb JF, Benedetti F, Geoffroy PA, Henriksen TEG, Lam RW, Murray G, Phelps J, Sit D, Swartz HA, Crowe M, Etain B, Frank E, Goel N, Haarman BCM, Inder M, Kallestad H, Jae Kim S, Martiny K, Meesters Y, Porter R, Riemersma-van der Lek RF, Ritter PS, Schulte PFJ, Scott J, Wu JC, Yu X, Chen S. The chronotherapeutic treatment of bipolar disorders: A systematic review and practice recommendations from the ISBD task force on chronotherapy and chronobiology. Bipolar Disord. 2019; 21(8):741-773. doi: 10.1111/bdi.12847.. <div class='header_tab'>Indication for this intervention.</div>The use of bright light therapy in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">bupropion</td>
  <td id="tableHTML_column_3">bupropion is a norepinephrine, dopamine inhibiteur recapture (NET, DAT), rel�che (NE, DA)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about bupropion</div><div class='header_tab'>Type of intervention.</div>bupropion is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is bupropion is a norepinephrine, dopamine inhibiteur recapture (NET, DAT), rel�che (NE, DA). <div class='header_tab'>Indication for this intervention.</div>The use of bupropion in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">carbamazepine</td>
  <td id="tableHTML_column_3">carbamazepine is a glutamate voltage-gated sodium and calcium channel blocker</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about carbamazepine</div><div class='header_tab'>Type of intervention.</div>carbamazepine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is carbamazepine is a glutamate voltage-gated sodium and calcium channel blocker. <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> Acute manic and mixed episodes in bipolar I disorder with a recommeded dose of Initial dose: 200 mg orally twice a day, Increase by 200 mg per day to achieve optimal response with a recommeded dose of Initial dose: 200 mg orally twice a day, Increase by 200 mg per day to achieve optimal response up to a maximum dose of 1600 mg per day up to a maximum dose of 1600 mg per day</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">carer focused intervention</td>
  <td id="tableHTML_column_3">carer focused intervention is a psychological interventions that aim to improve the experience of caregiving in bipolar disorder. Common components of these psychoeducational interventions include education about the nature of bipolar disorder, triggers and warning signs, treatment, management, and the impact on and role of caregivers. 



Baruch E, Pistrang N, Barker C. Psychological interventions for caregivers of people with bipolar disorder: A systematic review and meta-analysis. J Affect Disord. 2018; 236:187-198. doi: 10.1016/j.jad.2018.04.077.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about carer focused intervention</div><div class='header_tab'>Type of intervention.</div>carer focused intervention is a <u>Psychosocial</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>carer focused intervention carer focused intervention is a psychological interventions that aim to improve the experience of caregiving in bipolar disorder. Common components of these psychoeducational interventions include education about the nature of bipolar disorder, triggers and warning signs, treatment, management, and the impact on and role of caregivers. 



Baruch E, Pistrang N, Barker C. Psychological interventions for caregivers of people with bipolar disorder: A systematic review and meta-analysis. J Affect Disord. 2018; 236:187-198. doi: 10.1016/j.jad.2018.04.077.. <div class='header_tab'>Indication for this intervention.</div>The use of carer focused intervention in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">cariprazine</td>
  <td id="tableHTML_column_3">cariprazine is a dopamine, serotonin receptor partial agonist (D3/2, 5-HT1A), receptor antagonist (5-HT2B)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about cariprazine</div><div class='header_tab'>Type of intervention.</div>cariprazine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is cariprazine is a dopamine, serotonin receptor partial agonist (D3/2, 5-HT1A), receptor antagonist (5-HT2B). <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> Manic or Mixed Episodes associated with Bipolar I Disorder with a recommeded dose of 3�6 mg once daily with a recommeded dose of 3�6 mg once daily up to a maximum dose of 6 mg daily up to a maximum dose of 6 mg daily </li><li> Depressive Episodes associated with Bipolar Disorder with a recommeded dose of 1.5 or 3 mg once daily with a recommeded dose of 1.5 or 3 mg once daily up to a maximum dose of 3 mg daily up to a maximum dose of 3 mg daily</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">CBT</td>
  <td id="tableHTML_column_3">CBT is a is usually given in an individual or group format and aims at modifying maladaptive thoughts through cognitive restructuring. CBT has also behavioral components including interpersonal skills training, behavioral activation, or scheduling pleasurable life events to provide social reinforcement, problem solving, and �third-wave� components such as mindfulness, acceptance, and commitment. Some CBT programs may have only elements of behavioral or third-wave therapies without cognitive restructuring. 



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about CBT</div><div class='header_tab'>Type of intervention.</div>CBT is a <u>Psychosocial</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>CBT CBT is a is usually given in an individual or group format and aims at modifying maladaptive thoughts through cognitive restructuring. CBT has also behavioral components including interpersonal skills training, behavioral activation, or scheduling pleasurable life events to provide social reinforcement, problem solving, and �third-wave� components such as mindfulness, acceptance, and commitment. Some CBT programs may have only elements of behavioral or third-wave therapies without cognitive restructuring. 



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993. <div class='header_tab'>Indication for this intervention.</div>The use of CBT in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">celecoxib</td>
  <td id="tableHTML_column_3">celecoxib is a nonsteroidal anti-inflammatory drug (NSAID)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about celecoxib</div><div class='header_tab'>Type of intervention.</div>celecoxib is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is celecoxib is a nonsteroidal anti-inflammatory drug (NSAID). <div class='header_tab'>Indication for this intervention.</div>The use of celecoxib in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">chlorpromazine</td>
  <td id="tableHTML_column_3">chlorpromazine is a dopamine, serotonin receptor antagonist (D2, 5-HT2)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about chlorpromazine</div><div class='header_tab'>Type of intervention.</div>chlorpromazine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is chlorpromazine is a dopamine, serotonin receptor antagonist (D2, 5-HT2). <div class='header_tab'>Indication for this intervention.</div>The use of chlorpromazine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">choline</td>
  <td id="tableHTML_column_3">choline is a essential nutrient, precursor of acetylcholine and a methyl donor in various metabolic processes, and in lipid metabolism.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about choline</div><div class='header_tab'>Type of intervention.</div>choline is a <u>Nutraceutical</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>choline choline is a essential nutrient, precursor of acetylcholine and a methyl donor in various metabolic processes, and in lipid metabolism.. <div class='header_tab'>Indication for this intervention.</div>The use of choline in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">citalopram</td>
  <td id="tableHTML_column_3">citalopram is a serotonin reuptake inhibition (SERT)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about citalopram</div><div class='header_tab'>Type of intervention.</div>citalopram is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is citalopram is a serotonin reuptake inhibition (SERT). <div class='header_tab'>Indication for this intervention.</div>The use of citalopram in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">clonazepam</td>
  <td id="tableHTML_column_3">clonazepam is a GABA positive allosteric modulator, GABA-A receptor, benzodiazepine site</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about clonazepam</div><div class='header_tab'>Type of intervention.</div>clonazepam is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is clonazepam is a GABA positive allosteric modulator, GABA-A receptor, benzodiazepine site. <div class='header_tab'>Indication for this intervention.</div>The use of clonazepam in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">coenzyme Q10</td>
  <td id="tableHTML_column_3">coenzyme Q10 is a antioxidant, a lipid-soluble and essential cofactor in mitochondrial oxidative phosphorylation</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about coenzyme Q10</div><div class='header_tab'>Type of intervention.</div>coenzyme Q10 is a <u>Nutraceutical</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>coenzyme Q10 coenzyme Q10 is a antioxidant, a lipid-soluble and essential cofactor in mitochondrial oxidative phosphorylation. <div class='header_tab'>Indication for this intervention.</div>The use of coenzyme Q10 in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">creatine</td>
  <td id="tableHTML_column_3">creatine is a essential, non-proteinaceous amino acid constituent of skeletal muscle tissue of vertebrates, and is obtained through the diet or is endogenously synthesized in the body</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about creatine</div><div class='header_tab'>Type of intervention.</div>creatine is a <u>Nutraceutical</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>creatine creatine is a essential, non-proteinaceous amino acid constituent of skeletal muscle tissue of vertebrates, and is obtained through the diet or is endogenously synthesized in the body. <div class='header_tab'>Indication for this intervention.</div>The use of creatine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">desipramine</td>
  <td id="tableHTML_column_3">desipramine is a norepinephrine reuptake inhibitor (NET)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about desipramine</div><div class='header_tab'>Type of intervention.</div>desipramine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is desipramine is a norepinephrine reuptake inhibitor (NET). <div class='header_tab'>Indication for this intervention.</div>The use of desipramine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">dexamphetamine</td>
  <td id="tableHTML_column_3">dexamphetamine is a dopamine, norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about dexamphetamine</div><div class='header_tab'>Type of intervention.</div>dexamphetamine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is dexamphetamine is a dopamine, norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE). <div class='header_tab'>Indication for this intervention.</div>The use of dexamphetamine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">dextromethorphan</td>
  <td id="tableHTML_column_3">dextromethorphan is a NMDA receptor antagonist</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about dextromethorphan</div><div class='header_tab'>Type of intervention.</div>dextromethorphan is a <u>Nutraceutical</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>dextromethorphan dextromethorphan is a NMDA receptor antagonist. <div class='header_tab'>Indication for this intervention.</div>The use of dextromethorphan in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">divalproate</td>
  <td id="tableHTML_column_3">divalproate is a anticonvulsant may act through multiple mechanisms. It may increase gamma-aminobutyric acid (GABA)-mediated neurotransmission, modulate voltage-gated sodium channels, affect signaling systems including Wnt/beta-catenin and ERK pathways, and interfere with inositol and arachidonate metabolism.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about divalproate</div><div class='header_tab'>Type of intervention.</div>divalproate is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is divalproate is a anticonvulsant may act through multiple mechanisms. It may increase gamma-aminobutyric acid (GABA)-mediated neurotransmission, modulate voltage-gated sodium channels, affect signaling systems including Wnt/beta-catenin and ERK pathways, and interfere with inositol and arachidonate metabolism.. <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> �Acute management of mania associated with bipolar disorder with a recommeded dose of Initial dose is 750 mg daily increasing as rapidly as possible to achieve therapeutic response or desired plasma level. with a recommeded dose of Initial dose is 750 mg daily increasing as rapidly as possible to achieve therapeutic response or desired plasma level. up to a maximum dose of 60 mg/kg/day. up to a maximum dose of 60 mg/kg/day.</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Biological non-pharmacological</td>
  <td id="tableHTML_column_2">ECT</td>
  <td id="tableHTML_column_3">ECT is a a brain stimulation medical treatment used for severe mental health conditions, particularly when other treatments haven't worked well enough. During ECT, a small amount of electric current is passed through the brain, intentionally triggering a brief seizure. ECT devices are categorized as Class II devices for treating catatonia or severe major depressive episodes linked with major depressive disorder or bipolar disorder in patients aged 13 years and older who exhibit treatment resistance or necessitate a rapid response due to the severity of their psychiatric or medical condition.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about ECT</div><div class='header_tab'>Type of intervention.</div>ECT is a <u>Biological non-pharmacological</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>ECT ECT is a a brain stimulation medical treatment used for severe mental health conditions, particularly when other treatments haven't worked well enough. During ECT, a small amount of electric current is passed through the brain, intentionally triggering a brief seizure. ECT devices are categorized as Class II devices for treating catatonia or severe major depressive episodes linked with major depressive disorder or bipolar disorder in patients aged 13 years and older who exhibit treatment resistance or necessitate a rapid response due to the severity of their psychiatric or medical condition.. <div class='header_tab'>Indication for this intervention.</div>The use of ECT in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">endoxifen</td>
  <td id="tableHTML_column_3">endoxifen is a a secondary tamoxifen metabolite, potent antiestrogen exhibiting estrogen receptor alpha (ERa) binding</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about endoxifen</div><div class='header_tab'>Type of intervention.</div>endoxifen is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is endoxifen is a a secondary tamoxifen metabolite, potent antiestrogen exhibiting estrogen receptor alpha (ERa) binding. <div class='header_tab'>Indication for this intervention.</div>The use of endoxifen in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">erythropoietin</td>
  <td id="tableHTML_column_3">erythropoietin is a glycoprotein hormone which stimulates red blood cell formation</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about erythropoietin</div><div class='header_tab'>Type of intervention.</div>erythropoietin is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is erythropoietin is a glycoprotein hormone which stimulates red blood cell formation. <div class='header_tab'>Indication for this intervention.</div>The use of erythropoietin in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">escitalopram</td>
  <td id="tableHTML_column_3">escitalopram is a serotonin reuptake inhibitor (SERT)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about escitalopram</div><div class='header_tab'>Type of intervention.</div>escitalopram is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is escitalopram is a serotonin reuptake inhibitor (SERT). <div class='header_tab'>Indication for this intervention.</div>The use of escitalopram in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">esketamine</td>
  <td id="tableHTML_column_3">esketamine is a N-methyl-d-aspartate (NMDA) receptor antagonist and S-enantiomer of racemic ketamine</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about esketamine</div><div class='header_tab'>Type of intervention.</div>esketamine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is esketamine is a N-methyl-d-aspartate (NMDA) receptor antagonist and S-enantiomer of racemic ketamine. <div class='header_tab'>Indication for this intervention.</div>The use of esketamine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">eslicarbazepine</td>
  <td id="tableHTML_column_3">eslicarbazepine is a anticonvulsant acting as voltage-gated sodium channel blocker</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about eslicarbazepine</div><div class='header_tab'>Type of intervention.</div>eslicarbazepine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is eslicarbazepine is a anticonvulsant acting as voltage-gated sodium channel blocker. <div class='header_tab'>Indication for this intervention.</div>The use of eslicarbazepine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">family focused therapy</td>
  <td id="tableHTML_column_3">family focused therapy is a is a psychosocial intervention for adults and children with bipolar disorder and their caregivers (parents, spouse, or extended relatives), usually given in conjunction with pharmacotherapy. Programs involve conjoint sessions of psychoeducation regarding bipolar disorder, communication enhancement training, and problem-solving skills training.



Miklowitz DJ, Chung B. Family-Focused Therapy for Bipolar Disorder: Reflections on 30 Years of Research. Fam Process. 2016; 55(3):483-99. doi: 10.1111/famp.12237.



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about family focused therapy</div><div class='header_tab'>Type of intervention.</div>family focused therapy is a <u>Psychosocial</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>family focused therapy family focused therapy is a is a psychosocial intervention for adults and children with bipolar disorder and their caregivers (parents, spouse, or extended relatives), usually given in conjunction with pharmacotherapy. Programs involve conjoint sessions of psychoeducation regarding bipolar disorder, communication enhancement training, and problem-solving skills training.



Miklowitz DJ, Chung B. Family-Focused Therapy for Bipolar Disorder: Reflections on 30 Years of Research. Fam Process. 2016; 55(3):483-99. doi: 10.1111/famp.12237.



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. <div class='header_tab'>Indication for this intervention.</div>The use of family focused therapy in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">family/conjoint therapy</td>
  <td id="tableHTML_column_3">family/conjoint therapy is a have common elements including the involvement of the family, psychoeducation, and skills training. Family/conjoint therapy may be also labeled as family-focused psychoeducation, family-focused therapy, inpatient family intervention, behavioral family management, psychoeducational marital therapy, multifamily group psychoeducation, caregiver-focused psychoeducation, or conjoint psychoeducation. 



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021 Feb 1;78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about family/conjoint therapy</div><div class='header_tab'>Type of intervention.</div>family/conjoint therapy is a <u>Psychosocial</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>family/conjoint therapy family/conjoint therapy is a have common elements including the involvement of the family, psychoeducation, and skills training. Family/conjoint therapy may be also labeled as family-focused psychoeducation, family-focused therapy, inpatient family intervention, behavioral family management, psychoeducational marital therapy, multifamily group psychoeducation, caregiver-focused psychoeducation, or conjoint psychoeducation. 



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021 Feb 1;78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. <div class='header_tab'>Indication for this intervention.</div>The use of family/conjoint therapy in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">fluoxetine</td>
  <td id="tableHTML_column_3">fluoxetine is a serotonin reuptake inhibitor (SERT)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about fluoxetine</div><div class='header_tab'>Type of intervention.</div>fluoxetine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is fluoxetine is a serotonin reuptake inhibitor (SERT). <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> Depressive Episodes associated with Bipolar I Disorder in adults with a recommeded dose of Oral in combination with olanzapine: Start at 5 mg of oral olanzapine and 20 mg of fluoxetine once daily with a recommeded dose of Oral in combination with olanzapine: Start at 5 mg of oral olanzapine and 20 mg of fluoxetine once daily </li><li> Depressive Episodes associated with Bipolar I Disorder in children and adolescents with a recommeded dose of Oral in combination with olanzapine: Start at 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily with a recommeded dose of Oral in combination with olanzapine: Start at 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">folic acid</td>
  <td id="tableHTML_column_3">folic acid is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about folic acid</div><div class='header_tab'>Type of intervention.</div>folic acid is a <u>Nutraceutical</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>folic acid folic acid is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. <div class='header_tab'>Indication for this intervention.</div>The use of folic acid in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">functional remediation</td>
  <td id="tableHTML_column_3">functional remediation is a is an intervention that has been shown to improve outcomes in people with bipolar disorder by reducing global disability and improving interpersonal and occupational functioning. Unlike patient and family psychoeducation, cognitive behavioural therapy and interpersonal social rhythm therapy, it focuses on psychosocial adjustment rather than mood improvement or relapse prevention.  Vieta E, Torrent C. Functional remediation: the pathway from remission to recovery in bipolar disorder. World Psychiatry. 2016 Oct;15(3):288-289. doi: 10.1002/wps.20351.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about functional remediation</div><div class='header_tab'>Type of intervention.</div>functional remediation is a <u>Psychosocial</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>functional remediation functional remediation is a is an intervention that has been shown to improve outcomes in people with bipolar disorder by reducing global disability and improving interpersonal and occupational functioning. Unlike patient and family psychoeducation, cognitive behavioural therapy and interpersonal social rhythm therapy, it focuses on psychosocial adjustment rather than mood improvement or relapse prevention.  Vieta E, Torrent C. Functional remediation: the pathway from remission to recovery in bipolar disorder. World Psychiatry. 2016 Oct;15(3):288-289. doi: 10.1002/wps.20351.. <div class='header_tab'>Indication for this intervention.</div>The use of functional remediation in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">gabapentin</td>
  <td id="tableHTML_column_3">gabapentin is a glutamate alpha-2 delta calcium channel blocker</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about gabapentin</div><div class='header_tab'>Type of intervention.</div>gabapentin is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is gabapentin is a glutamate alpha-2 delta calcium channel blocker. <div class='header_tab'>Indication for this intervention.</div>The use of gabapentin in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">galantamine</td>
  <td id="tableHTML_column_3">galantamine is a acetylcholine enzyme inhibitor (acetylcholinesterase), alpha -7 nicotinic receptor positive allosteric modulator</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about galantamine</div><div class='header_tab'>Type of intervention.</div>galantamine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is galantamine is a acetylcholine enzyme inhibitor (acetylcholinesterase), alpha -7 nicotinic receptor positive allosteric modulator. <div class='header_tab'>Indication for this intervention.</div>The use of galantamine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">haloperidol</td>
  <td id="tableHTML_column_3">haloperidol is a dopamine receptor antagonist (D2)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about haloperidol</div><div class='header_tab'>Type of intervention.</div>haloperidol is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is haloperidol is a dopamine receptor antagonist (D2). <div class='header_tab'>Indication for this intervention.</div>The use of haloperidol in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">idazoxan</td>
  <td id="tableHTML_column_3">idazoxan is a selective a2 adrenergic receptor antagonist</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about idazoxan</div><div class='header_tab'>Type of intervention.</div>idazoxan is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is idazoxan is a selective a2 adrenergic receptor antagonist. <div class='header_tab'>Indication for this intervention.</div>The use of idazoxan in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">imipramine</td>
  <td id="tableHTML_column_3">imipramine is a serotonin, norepinephrine reuptake inhibitor (SERT and NET)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about imipramine</div><div class='header_tab'>Type of intervention.</div>imipramine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is imipramine is a serotonin, norepinephrine reuptake inhibitor (SERT and NET). <div class='header_tab'>Indication for this intervention.</div>The use of imipramine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">infliximab</td>
  <td id="tableHTML_column_3">infliximab is a monoclonal antibody acting as tumor necrosis factor (TNF-a) blocker</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about infliximab</div><div class='header_tab'>Type of intervention.</div>infliximab is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is infliximab is a monoclonal antibody acting as tumor necrosis factor (TNF-a) blocker. <div class='header_tab'>Indication for this intervention.</div>The use of infliximab in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">inositol</td>
  <td id="tableHTML_column_3">inositol is a nutrient supplement working as second messenger in several cellular processes</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about inositol</div><div class='header_tab'>Type of intervention.</div>inositol is a <u>Nutraceutical</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>inositol inositol is a nutrient supplement working as second messenger in several cellular processes. <div class='header_tab'>Indication for this intervention.</div>The use of inositol in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">insulin</td>
  <td id="tableHTML_column_3">insulin is a recombinant form of human insulin used to control hyperglycemia caused by Type 1 and Type 2 Diabetes</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about insulin</div><div class='header_tab'>Type of intervention.</div>insulin is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is insulin is a recombinant form of human insulin used to control hyperglycemia caused by Type 1 and Type 2 Diabetes. <div class='header_tab'>Indication for this intervention.</div>The use of insulin in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">Interpersonal and social rhythm therapy (IPSRT)</td>
  <td id="tableHTML_column_3">Interpersonal and social rhythm therapy (IPSRT) is a is an individual therapy with two components: interpersonal problem solving and social rhythm regularization, such as maintaining regular sleep/wake and other daily routines. 



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about Interpersonal and social rhythm therapy (IPSRT)</div><div class='header_tab'>Type of intervention.</div>Interpersonal and social rhythm therapy (IPSRT) is a <u>Psychosocial</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>Interpersonal and social rhythm therapy (IPSRT) Interpersonal and social rhythm therapy (IPSRT) is a is an individual therapy with two components: interpersonal problem solving and social rhythm regularization, such as maintaining regular sleep/wake and other daily routines. 



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. <div class='header_tab'>Indication for this intervention.</div>The use of Interpersonal and social rhythm therapy (IPSRT) in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">ketamine</td>
  <td id="tableHTML_column_3">ketamine is a glutamate NMDA antagonist</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about ketamine</div><div class='header_tab'>Type of intervention.</div>ketamine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is ketamine is a glutamate NMDA antagonist. <div class='header_tab'>Indication for this intervention.</div>The use of ketamine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">l-sulpride</td>
  <td id="tableHTML_column_3">l-sulpride is a prokinetic agent and peripheral dopamine D2 receptor antagonist</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about l-sulpride</div><div class='header_tab'>Type of intervention.</div>l-sulpride is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is l-sulpride is a prokinetic agent and peripheral dopamine D2 receptor antagonist. <div class='header_tab'>Indication for this intervention.</div>The use of l-sulpride in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">lamotrigine</td>
  <td id="tableHTML_column_3">lamotrigine is a glutamate voltage-gated sodium channel blocker</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about lamotrigine</div><div class='header_tab'>Type of intervention.</div>lamotrigine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is lamotrigine is a glutamate voltage-gated sodium channel blocker. <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> Bipolar Disorder in patients =18 years of age: maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy with a recommeded dose of 200 mg/day with a recommeded dose of 200 mg/day</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">levetiracetam</td>
  <td id="tableHTML_column_3">levetiracetam is a antiepileptic drug acting as a modulator of synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A in the brain</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about levetiracetam</div><div class='header_tab'>Type of intervention.</div>levetiracetam is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is levetiracetam is a antiepileptic drug acting as a modulator of synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A in the brain. <div class='header_tab'>Indication for this intervention.</div>The use of levetiracetam in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">licarbazepine</td>
  <td id="tableHTML_column_3">licarbazepine is a antiepileptic drug acting as voltage-gated sodium channels inhibitor</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about licarbazepine</div><div class='header_tab'>Type of intervention.</div>licarbazepine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is licarbazepine is a antiepileptic drug acting as voltage-gated sodium channels inhibitor. <div class='header_tab'>Indication for this intervention.</div>The use of licarbazepine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">lisdexamfetamine</td>
  <td id="tableHTML_column_3">lisdexamfetamine is a dopamine, norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about lisdexamfetamine</div><div class='header_tab'>Type of intervention.</div>lisdexamfetamine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is lisdexamfetamine is a dopamine, norepinephrine reuptake inhibitor (DAT, NET), releaser (DA, NE). <div class='header_tab'>Indication for this intervention.</div>The use of lisdexamfetamine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">lithium</td>
  <td id="tableHTML_column_3">lithium is a lithium enzyme modulator. Inhibition of Inositol monophosphatase, adenylyl-cyclase, GMP, glycogen synthase kinase 3</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about lithium</div><div class='header_tab'>Type of intervention.</div>lithium is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is lithium is a lithium enzyme modulator. Inhibition of Inositol monophosphatase, adenylyl-cyclase, GMP, glycogen synthase kinase 3. <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> Treatment of acute manic and mixed episodes in patients 7 years and older with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1.2 mEq/L with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1.2 mEq/L </li><li> Maintenance Treatment for Bipolar I Disorder (patients 7 years and older) with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1 mEq/L with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1 mEq/L</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">lithium</td>
  <td id="tableHTML_column_3">lithium is a lithium enzyme modulator. Inhibition of Inositol monophosphatase, adenylyl-cyclase, GMP, glycogen synthase kinase 4</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about lithium</div><div class='header_tab'>Type of intervention.</div>lithium is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is lithium is a lithium enzyme modulator. Inhibition of Inositol monophosphatase, adenylyl-cyclase, GMP, glycogen synthase kinase 4. <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> Treatment of acute manic and mixed episodes in patients 7 years and older with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1.2 mEq/L with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1.2 mEq/L </li><li> Maintenance Treatment for Bipolar I Disorder (patients 7 years and older) with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1 mEq/L with a recommeded dose of Titrate to serum lithium concentrations 0.8 to 1 mEq/L</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">lumateperone</td>
  <td id="tableHTML_column_3">lumateperone is a serotonin 5-HT2A receptor antagonist, a dopamine D2 receptor presynaptic partial agonist and postsynaptic antagonist, a D1 receptor�dependent modulator of glutamate, and a serotonin reuptake inhibitor.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about lumateperone</div><div class='header_tab'>Type of intervention.</div>lumateperone is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is lumateperone is a serotonin 5-HT2A receptor antagonist, a dopamine D2 receptor presynaptic partial agonist and postsynaptic antagonist, a D1 receptor�dependent modulator of glutamate, and a serotonin reuptake inhibitor.. <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate. with a recommeded dose of 42 mg administered orally once daily with a recommeded dose of 42 mg administered orally once daily up to a maximum dose of 42 mg/day up to a maximum dose of 42 mg/day</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">lurasidone</td>
  <td id="tableHTML_column_3">lurasidone is a dopamine, serotonin receptor antagonist (D2, 5-HT2)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about lurasidone</div><div class='header_tab'>Type of intervention.</div>lurasidone is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is lurasidone is a dopamine, serotonin receptor antagonist (D2, 5-HT2). <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> Depressive episodes associated with Bipolar I Disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate with a recommeded dose of 20 mg to 120 mg per day with a recommeded dose of 20 mg to 120 mg per day up to a maximum dose of 120 mg per day up to a maximum dose of 120 mg per day</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">melatonin</td>
  <td id="tableHTML_column_3">melatonin is a melatonin receptor agonist (Mel1 and Mel2)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about melatonin</div><div class='header_tab'>Type of intervention.</div>melatonin is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is melatonin is a melatonin receptor agonist (Mel1 and Mel2). <div class='header_tab'>Indication for this intervention.</div>The use of melatonin in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">memantine</td>
  <td id="tableHTML_column_3">memantine is a glutamate receptor antagonist (NMDA)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about memantine</div><div class='header_tab'>Type of intervention.</div>memantine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is memantine is a glutamate receptor antagonist (NMDA). <div class='header_tab'>Indication for this intervention.</div>The use of memantine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">minocycline</td>
  <td id="tableHTML_column_3">minocycline is a tetracycline antibiotic with pleiotropic antineuroinflammatory properties</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about minocycline</div><div class='header_tab'>Type of intervention.</div>minocycline is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is minocycline is a tetracycline antibiotic with pleiotropic antineuroinflammatory properties. <div class='header_tab'>Indication for this intervention.</div>The use of minocycline in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">moclobemide</td>
  <td id="tableHTML_column_3">moclobemide is a serotonin, norepinephrine, dopamine reversible enzyme inhibitor (MAO-A)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about moclobemide</div><div class='header_tab'>Type of intervention.</div>moclobemide is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is moclobemide is a serotonin, norepinephrine, dopamine reversible enzyme inhibitor (MAO-A). <div class='header_tab'>Indication for this intervention.</div>The use of moclobemide in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">modafinil</td>
  <td id="tableHTML_column_3">modafinil is a dopamine reuptake inhibitor (DAT)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about modafinil</div><div class='header_tab'>Type of intervention.</div>modafinil is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is modafinil is a dopamine reuptake inhibitor (DAT). <div class='header_tab'>Indication for this intervention.</div>The use of modafinil in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">n-acetyl cysteine</td>
  <td id="tableHTML_column_3">n-acetyl cysteine is a pharmacological antioxidant and cytoprotectant acting as a reductant of disulfide bonds, a scavenger of reactive oxygen species and/or a precursor for glutathione biosynthesis</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about n-acetyl cysteine</div><div class='header_tab'>Type of intervention.</div>n-acetyl cysteine is a <u>Nutraceutical</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>n-acetyl cysteine n-acetyl cysteine is a pharmacological antioxidant and cytoprotectant acting as a reductant of disulfide bonds, a scavenger of reactive oxygen species and/or a precursor for glutathione biosynthesis. <div class='header_tab'>Indication for this intervention.</div>The use of n-acetyl cysteine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">naltrexone</td>
  <td id="tableHTML_column_3">naltrexone is a opioid receptor antagonist (�,<U+03BA>)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about naltrexone</div><div class='header_tab'>Type of intervention.</div>naltrexone is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is naltrexone is a opioid receptor antagonist (�,<U+03BA>). <div class='header_tab'>Indication for this intervention.</div>The use of naltrexone in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">olanzapine</td>
  <td id="tableHTML_column_3">olanzapine is a dopamine, serotonin receptor antagonist (D2, 5-HT2)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about olanzapine</div><div class='header_tab'>Type of intervention.</div>olanzapine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is olanzapine is a dopamine, serotonin receptor antagonist (D2, 5-HT2). <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> Bipolar I Disorder (manic or mixed episodes) in adults with a recommeded dose of 5 mg to 20 mg/day with a recommeded dose of 5 mg to 20 mg/day up to a maximum dose of 20 mg/day up to a maximum dose of 20 mg/day </li><li> Bipolar I Disorder (manic or mixed episodes) in adolescents with a recommeded dose of 2.5 to 20 mg/day with a recommeded dose of 2.5 to 20 mg/day up to a maximum dose of 20 mg/day up to a maximum dose of 20 mg/day </li><li> Agitation associated with Bipolar I Mania in adults with a recommeded dose of IM: 10 mg (5 mg or 7.5 mg when clinically warranted) with a recommeded dose of IM: 10 mg (5 mg or 7.5 mg when clinically warranted)</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">omega3</td>
  <td id="tableHTML_column_3">omega3 is a polyunsaturated fatty acids mediate anti-inflammatory effects by suppressing lipogenic gene expression, increasing fatty acid beta-oxidation, increasing lipo-protein-lipase (LPL) expression, and influencing total body lipid accumulation.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about omega3</div><div class='header_tab'>Type of intervention.</div>omega3 is a <u>Nutraceutical</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>omega3 omega3 is a polyunsaturated fatty acids mediate anti-inflammatory effects by suppressing lipogenic gene expression, increasing fatty acid beta-oxidation, increasing lipo-protein-lipase (LPL) expression, and influencing total body lipid accumulation.. <div class='header_tab'>Indication for this intervention.</div>The use of omega3 in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">oxcarbazepine</td>
  <td id="tableHTML_column_3">oxcarbazepine is a glutamate voltage-gated sodium and calcium channel blocker</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about oxcarbazepine</div><div class='header_tab'>Type of intervention.</div>oxcarbazepine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is oxcarbazepine is a glutamate voltage-gated sodium and calcium channel blocker. <div class='header_tab'>Indication for this intervention.</div>The use of oxcarbazepine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">paliperidone</td>
  <td id="tableHTML_column_3">paliperidone is a dopamine, serotonin, norepinephrine receptor antagonist (D2, 5-HT2, NE alpha-2)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about paliperidone</div><div class='header_tab'>Type of intervention.</div>paliperidone is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is paliperidone is a dopamine, serotonin, norepinephrine receptor antagonist (D2, 5-HT2, NE alpha-2). <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> Schizoaffective disorder � adults with a recommeded dose of 3 - 12 mg/day with a recommeded dose of 3 - 12 mg/day up to a maximum dose of 12 mg/day up to a maximum dose of 12 mg/day</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">paroxetine</td>
  <td id="tableHTML_column_3">paroxetine is a serotonin reuptake inhibitor (SERT)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about paroxetine</div><div class='header_tab'>Type of intervention.</div>paroxetine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is paroxetine is a serotonin reuptake inhibitor (SERT). <div class='header_tab'>Indication for this intervention.</div>The use of paroxetine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">phenelzine</td>
  <td id="tableHTML_column_3">phenelzine is a serotonin, norepinephrine, dopamine enzyme inhibitor (MAO-A and -B)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about phenelzine</div><div class='header_tab'>Type of intervention.</div>phenelzine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is phenelzine is a serotonin, norepinephrine, dopamine enzyme inhibitor (MAO-A and -B). <div class='header_tab'>Indication for this intervention.</div>The use of phenelzine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">pindolol</td>
  <td id="tableHTML_column_3">pindolol is a beta adrenoceptor antagonist</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about pindolol</div><div class='header_tab'>Type of intervention.</div>pindolol is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is pindolol is a beta adrenoceptor antagonist. <div class='header_tab'>Indication for this intervention.</div>The use of pindolol in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">pioglitazone</td>
  <td id="tableHTML_column_3">pioglitazone is a thiazolidinediones act as synthetic ligands for peroxisome proliferator-activated receptors (PPARs). Pioglitazone improves glycaemic control by improving insulin sensitivity through its action on PPAR gamma 1 and PPAR gamma 2 and by affecting lipid metabolism through its action on PPAR alpha.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about pioglitazone</div><div class='header_tab'>Type of intervention.</div>pioglitazone is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is pioglitazone is a thiazolidinediones act as synthetic ligands for peroxisome proliferator-activated receptors (PPARs). Pioglitazone improves glycaemic control by improving insulin sensitivity through its action on PPAR gamma 1 and PPAR gamma 2 and by affecting lipid metabolism through its action on PPAR alpha.. <div class='header_tab'>Indication for this intervention.</div>The use of pioglitazone in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">placebo</td>
  <td id="tableHTML_column_3">placebo is a a therapeutic effect, drug or non-drug, or part thereof, which objectively has no specific pharmacodynamic action in the condition being treated.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about placebo</div><div class='header_tab'>Type of intervention.</div>placebo is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is placebo is a a therapeutic effect, drug or non-drug, or part thereof, which objectively has no specific pharmacodynamic action in the condition being treated.. <div class='header_tab'>Indication for this intervention.</div>The use of placebo in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">pramipexole</td>
  <td id="tableHTML_column_3">pramipexole is a dopamine receptor agonist (D2)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about pramipexole</div><div class='header_tab'>Type of intervention.</div>pramipexole is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is pramipexole is a dopamine receptor agonist (D2). <div class='header_tab'>Indication for this intervention.</div>The use of pramipexole in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">pregnenolone</td>
  <td id="tableHTML_column_3">pregnenolone is a precursor to gonadal steroid hormones and the adrenal corticosteroids</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about pregnenolone</div><div class='header_tab'>Type of intervention.</div>pregnenolone is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is pregnenolone is a precursor to gonadal steroid hormones and the adrenal corticosteroids. <div class='header_tab'>Indication for this intervention.</div>The use of pregnenolone in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">psychoeducation</td>
  <td id="tableHTML_column_3">psychoeducation is a an intervention that consists of six or more sessions in which patients, and sometimes family members, are given information about disease characteristics, the importance of adherence to treatment, early recognition of prodromal signs of relapse/recurrence, management of mood symptoms or comorbid conditions, and lifestyle regularity.



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about psychoeducation</div><div class='header_tab'>Type of intervention.</div>psychoeducation is a <u>Psychosocial</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>psychoeducation psychoeducation is a an intervention that consists of six or more sessions in which patients, and sometimes family members, are given information about disease characteristics, the importance of adherence to treatment, early recognition of prodromal signs of relapse/recurrence, management of mood symptoms or comorbid conditions, and lifestyle regularity.



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. <div class='header_tab'>Indication for this intervention.</div>The use of psychoeducation in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">psychoeducation brief �</td>
  <td id="tableHTML_column_3">psychoeducation brief � is a is a brief form of psychoeducation consisting of fewer than 3 psychoeducation sessions delivered in a group, family, or individual format. Such interventions sometimes include skills training tasks for patients with bipolar disorder, such as regulating sleep-wake cycles or monitoring prodromal symptoms. A self-guided workbook is often included.



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021 Feb 1;78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about psychoeducation brief �</div><div class='header_tab'>Type of intervention.</div>psychoeducation brief � is a <u>Psychosocial</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>psychoeducation brief � psychoeducation brief � is a is a brief form of psychoeducation consisting of fewer than 3 psychoeducation sessions delivered in a group, family, or individual format. Such interventions sometimes include skills training tasks for patients with bipolar disorder, such as regulating sleep-wake cycles or monitoring prodromal symptoms. A self-guided workbook is often included.



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021 Feb 1;78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. <div class='header_tab'>Indication for this intervention.</div>The use of psychoeducation brief � in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">psychoeducation group</td>
  <td id="tableHTML_column_3">psychoeducation group is a is a psychoeducational program provided in a group format.



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about psychoeducation group</div><div class='header_tab'>Type of intervention.</div>psychoeducation group is a <u>Psychosocial</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>psychoeducation group psychoeducation group is a is a psychoeducational program provided in a group format.



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. <div class='header_tab'>Indication for this intervention.</div>The use of psychoeducation group in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">psychoeducation individual</td>
  <td id="tableHTML_column_3">psychoeducation individual is a is a psychoeducational program provided in an individual format.



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about psychoeducation individual</div><div class='header_tab'>Type of intervention.</div>psychoeducation individual is a <u>Psychosocial</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>psychoeducation individual psychoeducation individual is a is a psychoeducational program provided in an individual format.



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. <div class='header_tab'>Indication for this intervention.</div>The use of psychoeducation individual in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">quetiapine</td>
  <td id="tableHTML_column_3">quetiapine is a dopamine, serotonin, norepinephrine receptor antagonist (D2, 5-HT2) and reuptake inhibitor (NET)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about quetiapine</div><div class='header_tab'>Type of intervention.</div>quetiapine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is quetiapine is a dopamine, serotonin, norepinephrine receptor antagonist (D2, 5-HT2) and reuptake inhibitor (NET). <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> Bipolar Mania- Adults Monotherapy with a recommeded dose of 400� 800 mg/day with a recommeded dose of 400� 800 mg/day up to a maximum dose of 800 mg/day up to a maximum dose of 800 mg/day </li><li> Bipolar Mania- Children and Adolescents (10 to 17 years), Monotherapy with a recommeded dose of 400�600 mg/day with a recommeded dose of 400�600 mg/day up to a maximum dose of 600 mg/day up to a maximum dose of 600 mg/day </li><li> Bipolar Depression- Adults with a recommeded dose of 300 mg/day with a recommeded dose of 300 mg/day up to a maximum dose of 300 mg/day up to a maximum dose of 300 mg/day</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">ramelteon</td>
  <td id="tableHTML_column_3">ramelteon is a melatonin receptor agonist (Mel1 and Mel2)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about ramelteon</div><div class='header_tab'>Type of intervention.</div>ramelteon is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is ramelteon is a melatonin receptor agonist (Mel1 and Mel2). <div class='header_tab'>Indication for this intervention.</div>The use of ramelteon in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">riluzole</td>
  <td id="tableHTML_column_3">riluzole is a glutamate antagonist</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about riluzole</div><div class='header_tab'>Type of intervention.</div>riluzole is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is riluzole is a glutamate antagonist. <div class='header_tab'>Indication for this intervention.</div>The use of riluzole in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">risperidone</td>
  <td id="tableHTML_column_3">risperidone is a dopamine, serotonin, norepinephrine receptor antagonist (D2, 5-HT2, NE alpha-2)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about risperidone</div><div class='header_tab'>Type of intervention.</div>risperidone is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is risperidone is a dopamine, serotonin, norepinephrine receptor antagonist (D2, 5-HT2, NE alpha-2). <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> Bipolar mania � adults with a recommeded dose of 1-6 mg/day with a recommeded dose of 1-6 mg/day up to a maximum dose of 6 mg/day up to a maximum dose of 6 mg/day </li><li> Bipolar mania in children/ adolescents with a recommeded dose of 0.5-6 mg/day with a recommeded dose of 0.5-6 mg/day up to a maximum dose of 6 mg/day up to a maximum dose of 6 mg/day</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Biological non-pharmacological</td>
  <td id="tableHTML_column_2">rTMS</td>
  <td id="tableHTML_column_3">rTMS is a is a non-invasive brain stimulation technique that uses electromagnetic pulses delivered by a powerful and focused electromagnetic coil to induce electrical currents in neural tissue, modulating neuronal activity in targeted brain regions.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about rTMS</div><div class='header_tab'>Type of intervention.</div>rTMS is a <u>Biological non-pharmacological</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>rTMS rTMS is a is a non-invasive brain stimulation technique that uses electromagnetic pulses delivered by a powerful and focused electromagnetic coil to induce electrical currents in neural tissue, modulating neuronal activity in targeted brain regions.. <div class='header_tab'>Indication for this intervention.</div>The use of rTMS in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">sAME</td>
  <td id="tableHTML_column_3">sAME is a it affects the regulation of a wide range of critical components of neurotransmission and is involved in three central metabolic pathways including trans-sulfuration, transaminopropylation, and methylation</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about sAME</div><div class='header_tab'>Type of intervention.</div>sAME is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is sAME is a it affects the regulation of a wide range of critical components of neurotransmission and is involved in three central metabolic pathways including trans-sulfuration, transaminopropylation, and methylation. <div class='header_tab'>Indication for this intervention.</div>The use of sAME in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">selegiline</td>
  <td id="tableHTML_column_3">selegiline is a dopamine, norepinephrine, serotonin enzyme inhibitor (MAO-B and -A)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about selegiline</div><div class='header_tab'>Type of intervention.</div>selegiline is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is selegiline is a dopamine, norepinephrine, serotonin enzyme inhibitor (MAO-B and -A). <div class='header_tab'>Indication for this intervention.</div>The use of selegiline in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">sertraline</td>
  <td id="tableHTML_column_3">sertraline is a serotonin reuptake inhibitor (SERT)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about sertraline</div><div class='header_tab'>Type of intervention.</div>sertraline is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is sertraline is a serotonin reuptake inhibitor (SERT). <div class='header_tab'>Indication for this intervention.</div>The use of sertraline in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Biological non-pharmacological</td>
  <td id="tableHTML_column_2">sham</td>
  <td id="tableHTML_column_3">sham is a is a control procedure or intervention that is similar to, but omits a key therapeutic element of the treatment or procedure under investigation</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about sham</div><div class='header_tab'>Type of intervention.</div>sham is a <u>Biological non-pharmacological</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>sham sham is a is a control procedure or intervention that is similar to, but omits a key therapeutic element of the treatment or procedure under investigation. <div class='header_tab'>Indication for this intervention.</div>The use of sham in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">supportive therapy</td>
  <td id="tableHTML_column_3">supportive therapy is a Supportive therapy is an unstructured therapy without specific psychological techniques other than those common to all approaches and may be delivered in an individual or group format. It is based on the assumption that the therapeutic alliance is the crucial element of therapy and that relief from personal problems can be achieved through discussion with others.



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about supportive therapy</div><div class='header_tab'>Type of intervention.</div>supportive therapy is a <u>Psychosocial</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>supportive therapy supportive therapy is a Supportive therapy is an unstructured therapy without specific psychological techniques other than those common to all approaches and may be delivered in an individual or group format. It is based on the assumption that the therapeutic alliance is the crucial element of therapy and that relief from personal problems can be achieved through discussion with others.



Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A. Adjunctive Psychotherapy for Bipolar Disorder: A Systematic Review and Component Network Meta-analysis. JAMA Psychiatry. 2021; 78(2):141-150. doi: 10.1001/jamapsychiatry.2020.2993.. <div class='header_tab'>Indication for this intervention.</div>The use of supportive therapy in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">t3 hormone</td>
  <td id="tableHTML_column_3">t3 hormone is a Exogenous triiodothyronine exerts the effects of the endogenous thyroid T3 hormone</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about t3 hormone</div><div class='header_tab'>Type of intervention.</div>t3 hormone is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is t3 hormone is a Exogenous triiodothyronine exerts the effects of the endogenous thyroid T3 hormone. <div class='header_tab'>Indication for this intervention.</div>The use of t3 hormone in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">t4 hormone</td>
  <td id="tableHTML_column_3">t4 hormone is a Exogenous T4 hormone refers to synthetic or supplemental thyroxine, which is a form of thyroid hormone</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about t4 hormone</div><div class='header_tab'>Type of intervention.</div>t4 hormone is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is t4 hormone is a Exogenous T4 hormone refers to synthetic or supplemental thyroxine, which is a form of thyroid hormone. <div class='header_tab'>Indication for this intervention.</div>The use of t4 hormone in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">tamoxifen</td>
  <td id="tableHTML_column_3">tamoxifen is a selective estrogen receptor modulator</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about tamoxifen</div><div class='header_tab'>Type of intervention.</div>tamoxifen is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is tamoxifen is a selective estrogen receptor modulator. <div class='header_tab'>Indication for this intervention.</div>The use of tamoxifen in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Psychosocial</td>
  <td id="tableHTML_column_2">TAU</td>
  <td id="tableHTML_column_3">TAU is a treatment as usual</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about TAU</div><div class='header_tab'>Type of intervention.</div>TAU is a <u>Psychosocial</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>TAU TAU is a treatment as usual. <div class='header_tab'>Indication for this intervention.</div>The use of TAU in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Biological non-pharmacological</td>
  <td id="tableHTML_column_2">tDCS</td>
  <td id="tableHTML_column_3">tDCS is a is a non-invasive neuromodulation technique that delivers a well-tolerated electrical current to the brain through scalp electrodes.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about tDCS</div><div class='header_tab'>Type of intervention.</div>tDCS is a <u>Biological non-pharmacological</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>tDCS tDCS is a is a non-invasive neuromodulation technique that delivers a well-tolerated electrical current to the brain through scalp electrodes.. <div class='header_tab'>Indication for this intervention.</div>The use of tDCS in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">topiramate</td>
  <td id="tableHTML_column_3">topiramate is a GABA, glutamate facilitation of GABA transmission, receptor antagonist on AMPA and KA</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about topiramate</div><div class='header_tab'>Type of intervention.</div>topiramate is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is topiramate is a GABA, glutamate facilitation of GABA transmission, receptor antagonist on AMPA and KA. <div class='header_tab'>Indication for this intervention.</div>The use of topiramate in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Biological non-pharmacological</td>
  <td id="tableHTML_column_2">total sleep deprivation</td>
  <td id="tableHTML_column_3">total sleep deprivation is a involves being deprived of total sleep for approximately 36 hours straight, from daytime until next day�s evening. Treatment usually consists in one to six cycles.



Ramirez-Mahaluf JP, Rozas-Serri E, Ivanovic-Zuvic F, Risco L, V�hringer PA. Effectiveness of Sleep Deprivation in Treating Acute Bipolar Depression as Augmentation Strategy: A Systematic Review and Meta-Analysis. Front Psychiatry. 2020 Feb 25;11:70. doi: 10.3389/fpsyt.2020.00070.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about total sleep deprivation</div><div class='header_tab'>Type of intervention.</div>total sleep deprivation is a <u>Biological non-pharmacological</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>total sleep deprivation total sleep deprivation is a involves being deprived of total sleep for approximately 36 hours straight, from daytime until next day�s evening. Treatment usually consists in one to six cycles.



Ramirez-Mahaluf JP, Rozas-Serri E, Ivanovic-Zuvic F, Risco L, V�hringer PA. Effectiveness of Sleep Deprivation in Treating Acute Bipolar Depression as Augmentation Strategy: A Systematic Review and Meta-Analysis. Front Psychiatry. 2020 Feb 25;11:70. doi: 10.3389/fpsyt.2020.00070.. <div class='header_tab'>Indication for this intervention.</div>The use of total sleep deprivation in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">tranylcypromine</td>
  <td id="tableHTML_column_3">tranylcypromine is a serotonin, norepinephrine, dopamine enzyme inhibitor (MAO-A and -B), releaser (DA, NE)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about tranylcypromine</div><div class='header_tab'>Type of intervention.</div>tranylcypromine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is tranylcypromine is a serotonin, norepinephrine, dopamine enzyme inhibitor (MAO-A and -B), releaser (DA, NE). <div class='header_tab'>Indication for this intervention.</div>The use of tranylcypromine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">valnoctamide</td>
  <td id="tableHTML_column_3">valnoctamide is a a central nervous system active chiral constitutional isomer of valpromide, the corresponding amide of valproic acid, which exhibits stereoselective pharmacokinetics in humans and animals.</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about valnoctamide</div><div class='header_tab'>Type of intervention.</div>valnoctamide is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is valnoctamide is a a central nervous system active chiral constitutional isomer of valpromide, the corresponding amide of valproic acid, which exhibits stereoselective pharmacokinetics in humans and animals.. <div class='header_tab'>Indication for this intervention.</div>The use of valnoctamide in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">venlafaxine</td>
  <td id="tableHTML_column_3">venlafaxine is a serotonin, norepinephrine reuptake inhibitor (SERT and NET)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about venlafaxine</div><div class='header_tab'>Type of intervention.</div>venlafaxine is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is venlafaxine is a serotonin, norepinephrine reuptake inhibitor (SERT and NET). <div class='header_tab'>Indication for this intervention.</div>The use of venlafaxine in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">verapamil</td>
  <td id="tableHTML_column_3">verapamil is a non-dihydropyridine calcium channel blocker</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about verapamil</div><div class='header_tab'>Type of intervention.</div>verapamil is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is verapamil is a non-dihydropyridine calcium channel blocker. <div class='header_tab'>Indication for this intervention.</div>The use of verapamil in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">vitD3</td>
  <td id="tableHTML_column_3">vitD3 is a exogenous vitamine D3 is commonly used to supplement dietary intake and ensure adequate levels of vitamin D</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about vitD3</div><div class='header_tab'>Type of intervention.</div>vitD3 is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is vitD3 is a exogenous vitamine D3 is commonly used to supplement dietary intake and ensure adequate levels of vitamin D. <div class='header_tab'>Indication for this intervention.</div>The use of vitD3 in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Nutraceutical</td>
  <td id="tableHTML_column_2">withania somnifer</td>
  <td id="tableHTML_column_3">withania somnifer is a is a medicinal herb reported to have antioxidant, anti-inflammatory, and immunomodulatory properties</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about withania somnifer</div><div class='header_tab'>Type of intervention.</div>withania somnifer is a <u>Nutraceutical</u> intervention. <br><div class='header_tab'>Description of the intervention.</div>withania somnifer withania somnifer is a is a medicinal herb reported to have antioxidant, anti-inflammatory, and immunomodulatory properties. <div class='header_tab'>Indication for this intervention.</div>The use of withania somnifer in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">ziprasidone</td>
  <td id="tableHTML_column_3">ziprasidone is a dopamine, serotonin receptor antagonist (D2, 5-HT2)</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about ziprasidone</div><div class='header_tab'>Type of intervention.</div>ziprasidone is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is ziprasidone is a dopamine, serotonin receptor antagonist (D2, 5-HT2). <div class='header_tab'>Indication for this intervention.</div><u>This intervention is indicated in</u> <ul class='list_inter'><li> Acute treatment as monotherapy of manic or mixed episodes associated with bipolar I disorder with a recommeded dose of 40-80 mg twice daily with a recommeded dose of 40-80 mg twice daily </li><li> Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate with a recommeded dose of 40-80 mg twice daily with a recommeded dose of 40-80 mg twice daily</ul></td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
<tr>
  <td id="tableHTML_column_1">Pharmacological</td>
  <td id="tableHTML_column_2">zonisamide</td>
  <td id="tableHTML_column_3">zonisamide is a sulfonamide anticonvulsant may act by blocking repetitive firing of voltage-sensitive sodium channels and reducing voltage-sensitive T-type calcium currents</td>
  <td id="tableHTML_column_4"><div class='desc_tab'>More information about zonisamide</div><div class='header_tab'>Type of intervention.</div>zonisamide is a <u>Pharmacological</u> intervention. <br><div class='header_tab'>Mecanism of action.</div> Its mechanism of action is zonisamide is a sulfonamide anticonvulsant may act by blocking repetitive firing of voltage-sensitive sodium channels and reducing voltage-sensitive T-type calcium currents. <div class='header_tab'>Indication for this intervention.</div>The use of zonisamide in BD is off-label in most countries.</td>
  <td id="tableHTML_column_5"><button onclick="openModal(this)">Learn more</button></td>
</tr>
</tbody>
</table>
